Kim BS, et al. - Experts determined if the systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease was reduced by ustekinumab, measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). In patients with psoriasis, ustekinumab treatment was seen to be notably associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease.